Related Experiment Video

Updated: Aug 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

What's Next for Sotorasib in NSCLC?

    Cancer Discovery
    |March 17, 2023
    PubMed

    Insights

    Sotorasib significantly reduced disease progression or death risk by 34% compared to docetaxel in the CodeBreaK 200 trial. While not improving overall survival, its lower toxicity may offer a better treatment option for patients.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Non-small cell lung cancer (NSCLC) treatment often involves chemotherapy.
    • Targeted therapies are emerging for specific genetic mutations.

    Purpose of the Study:

    • To compare the efficacy and safety of sotorasib versus docetaxel in patients with KRAS G12C-mutated NSCLC.
    • To evaluate disease progression, death, and overall survival outcomes.

    Main Methods:

    • The CodeBreaK 200 trial was a randomized, open-label study.
    • Patients received either sotorasib or docetaxel.

    Main Results:

    • Sotorasib demonstrated a 34% relative risk reduction in disease progression or death compared to docetaxel.
    • No significant improvement in overall survival was observed with sotorasib.
    • Sotorasib exhibited a more favorable toxicity profile.

    Conclusions:

    • Sotorasib offers a survival benefit in terms of progression-free survival and reduced toxicity compared to docetaxel for KRAS G12C-mutated NSCLC.
    • Further research, including subgroup analyses and combination therapies, is warranted to optimize KRAS inhibitor treatment.

    More Related Videos

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.0K
    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.8K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K